Your email has been successfully added to our mailing list.

×
0.00344827586206889 0 -0.010344827586207 0 0 0 0 0
Stock impact report

BioCryst stock rallies on start of coronavirus drug study [MarketWatch]

BioCryst Pharmaceuticals, Inc. (BCRX) 
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: biocryst.gcs-web.com/investor-relations
Company Research Source: MarketWatch
BioCryst Pharmaceuticals Inc. shares rallied in the extended session Thursday after the drug maker said it was starting a clinical trial to test its COVID-19 treatment. BioCryst shares surged 35% after hours, following a 3.5% rise to close the regular session at $2.07. The company said it opened a randomized, double-blind, placebo-controlled clinical trial to test the drug galidesivir in treating patients with COVID-19. The study, which is being funded by the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases, will be conducted in Brazil, the company said. Many drug companies have recently started development of either COVID-19 treatments or vaccines. Show less Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for BCRX alerts
Opt-in for
BCRX alerts

from News Quantified
Opt-in for
BCRX alerts

from News Quantified